Biotech M&A Tracker 2026
Live tracker of biotech/biopharma acquisitions announced in 2026 — target, acquirer, deal value, structure, premium, and a one-line “why it matters.”
The page focuses on control transactions at the company level across public and private biotech/biopharma names. BioBucks updates the tracker as new deals are announced; the daily newsletter adds the read-through on what those deals signal for valuation, risk appetite, and strategic priorities.
Last updated: 17 May 2026
Get 2026 biotech M&A updates as they land (free)
The tracker refreshes regularly — the BioBucks newsletter flags new deals and credible rumors daily (in ~5 mins).
Read by 2,000+ VC, BD&L, and public biotech investors. No spam. Unsubscribe anytime.
2026 biotech M&A market snapshot
- 33 transactions are currently tracked here, spanning both public and private biotech/biopharma targets and selected high-signal biopharma-enabling infrastructure deals.
- Largest disclosed deal so far: Organon / Sun Pharma at roughly US$11.75B enterprise value, followed by Arcellx / Gilead at roughly US$7.8B implied equity value and Centessa / Lilly at up to US$7.8B.
- The May tape added a fresh wave of strategic, financial-sponsor, diagnostics-infrastructure, and platform-driven activity, including Angelini / Catalyst, Roche / PathAI, Bayer / Perfuse, UCB / Candid, ARCHIMED / Esperion, and Pathos AI / DeuterOncology.
- The tape still looks selective rather than indiscriminate: buyers are paying for approved products, NDA-ready / late-stage assets, clear strategic platform fit, or enabling infrastructure that strengthens commercial, diagnostics, or AI-enabled precision-medicine capabilities.
May 2026
Catalyst Pharmaceuticals
07-May-2026
Acquirer: Angelini Pharma
Total deal value: Approximately US$4.1B equity value
|
Upfront: US$31.50/share in cash
Structure: All-cash acquisition
|
Type: Public
|
1D Premium: 21% to unaffected close / 28% to 30-day VWAP
Therapeutic area: Rare disease / Neurology / Neuromuscular disease
|
Stage / lead assets: Commercial rare-disease portfolio including FIRDAPSE for Lambert-Eaton myasthenic syndrome
Why it matters: Angelini is using M&A to enter the U.S. market and scale its brain-health / rare-disease presence around a commercial neuromuscular platform. The read-through is that commercial rare-disease assets with concentrated specialist infrastructure remain strategic, particularly for ex-U.S. buyers seeking a U.S. beachhead rather than building one organically.
DeuterOncology
06-May-2026
Acquirer: Pathos AI
Total deal value: Not disclosed
|
Upfront: Not disclosed
Structure: Acquisition of a majority stake
|
Type: Private
|
1D Premium: N/A
Therapeutic area: Oncology / Precision oncology
|
Stage / lead assets: DO-2, a third-generation MET kinase inhibitor for MET-altered cancers
Why it matters: This is a smaller, undisclosed-value control transaction, but strategically notable because Pathos is positioning it as an AI-sourced clinical oncology acquisition. The read-through is that AI-native developers are starting to use proprietary asset-screening platforms not just to design programs internally, but to identify and buy clinical-stage assets with differentiated early data.
Perfuse Therapeutics
06-May-2026
Acquirer: Bayer
Total deal value: Up to US$2.45B
|
Upfront: US$300M cash
Structure: Acquisition (cash upfront + milestone payments)
|
Type: Private
|
1D Premium: N/A
Therapeutic area: Ophthalmology / Retinal disease
|
Stage / lead assets: PER-001, a Phase 2 small-molecule endothelin receptor antagonist for glaucoma and diabetic retinopathy
Why it matters: Bayer is adding a clinical-stage ophthalmology asset and mechanism that could broaden its eye-care pipeline beyond existing retinal franchises. The read-through is that ophthalmology remains a live M&A lane when the target offers a differentiated biology angle and a plausible path into large, high-burden diseases such as glaucoma and diabetic retinopathy.